NASDAQ:SHPH - US8256933024 - Common Stock
The current stock price of SHPH is 3.37 USD. In the past month the price decreased by -5.71%. In the past year, price decreased by -93.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.89 | 372.18B | ||
AMGN | AMGEN INC | 13.06 | 153.38B | ||
GILD | GILEAD SCIENCES INC | 14.45 | 138.78B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.46 | 101.88B | ||
REGN | REGENERON PHARMACEUTICALS | 12.53 | 60.59B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.44B | ||
ARGX | ARGENX SE - ADR | 75.61 | 42.89B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.56 | 38.72B | ||
INSM | INSMED INC | N/A | 30.50B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.88B | ||
NTRA | NATERA INC | N/A | 22.92B | ||
BIIB | BIOGEN INC | 8.57 | 20.12B |
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
SHUTTLE PHARMACEUTICALS HOLD
401 Professional Drive, Suite 260
Gaithersburg MARYLAND US
Employees: 9
Phone: 12404034212
The current stock price of SHPH is 3.37 USD. The price increased by 2.12% in the last trading session.
The exchange symbol of SHUTTLE PHARMACEUTICALS HOLD is SHPH and it is listed on the Nasdaq exchange.
SHPH stock is listed on the Nasdaq exchange.
SHUTTLE PHARMACEUTICALS HOLD (SHPH) has a market capitalization of 3.61M USD. This makes SHPH a Nano Cap stock.
SHUTTLE PHARMACEUTICALS HOLD (SHPH) currently has 9 employees.
SHUTTLE PHARMACEUTICALS HOLD (SHPH) has a support level at 3.29 and a resistance level at 3.32. Check the full technical report for a detailed analysis of SHPH support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SHPH does not pay a dividend.
SHUTTLE PHARMACEUTICALS HOLD (SHPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-64.49).
The outstanding short interest for SHUTTLE PHARMACEUTICALS HOLD (SHPH) is 1.67% of its float. Check the ownership tab for more information on the SHPH short interest.
ChartMill assigns a fundamental rating of 1 / 10 to SHPH. SHPH may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SHPH reported a non-GAAP Earnings per Share(EPS) of -64.49. The EPS increased by 9.87% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -220.59% | ||
ROE | -336.77% | ||
Debt/Equity | 0.12 |